AGTR2 and ductal breast carcinoma in situ: AT2 receptor is expressed at low levels in normal breast ducts, however; its expression significantly increases under pathological conditions such as breast hyperplasia, Ductal Carcinoma In Situ (DCIS), and aggressive breast cancer [229].